Pharming Group NV (PHAR)
9.68
-0.12
(-1.22%)
USD |
NASDAQ |
Oct 06, 16:00
Pharming Group Gross Profit Margin (Quarterly) : 80.56% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.56% |
| March 31, 2026 | 90.83% |
| December 31, 2025 | 77.18% |
| September 30, 2025 | 92.70% |
| June 30, 2025 | 90.34% |
| March 31, 2025 | 89.48% |
| December 31, 2024 | 83.96% |
| September 30, 2024 | 90.89% |
| June 30, 2024 | 89.20% |
| March 31, 2024 | 84.91% |
| December 31, 2023 | 81.95% |
| September 30, 2023 | 87.56% |
| June 30, 2023 | 89.57% |
| March 31, 2023 | 90.42% |
| December 31, 2022 | 75.75% |
| September 30, 2022 | 95.61% |
| June 30, 2022 | 91.97% |
| March 31, 2022 | 89.54% |
| December 31, 2021 | 65.16% |
| September 30, 2021 | 88.63% |
| June 30, 2021 | 90.65% |
| March 31, 2021 | 88.88% |
| December 31, 2020 | 84.13% |
| September 30, 2020 | 85.81% |
| June 30, 2020 | 84.36% |
| Date | Value |
|---|---|
| March 31, 2020 | 85.61% |
| December 31, 2019 | 88.88% |
| September 30, 2019 | 82.81% |
| June 30, 2019 | 83.66% |
| March 31, 2019 | 80.77% |
| December 31, 2018 | 72.90% |
| September 30, 2018 | 81.00% |
| June 30, 2018 | 81.95% |
| March 31, 2018 | 79.76% |
| December 31, 2017 | 86.24% |
| September 30, 2017 | 83.66% |
| June 30, 2017 | 87.09% |
| March 31, 2017 | 89.02% |
| December 31, 2016 | 79.79% |
| September 30, 2016 | 64.08% |
| June 30, 2016 | 55.98% |
| March 31, 2016 | 70.33% |
| December 31, 2015 | 54.44% |
| September 30, 2015 | 57.49% |
| June 30, 2015 | 60.95% |
| March 31, 2015 | 43.71% |
| December 31, 2014 | 95.59% |
| September 30, 2014 | 42.26% |
| June 30, 2014 | 80.45% |
| March 31, 2014 | 14.24% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ProQR Therapeutics NV | 91.93% |
| NewAmsterdam Pharma Co. NV | 98.41% |
| argenx SE | -- |
| Nektar Therapeutics | 98.46% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 3.52% |
| Return on Assets | 1.91% |
| Return on Invested Capital | 2.37% |
| Profit Margin (Quarterly) | 1.77% |
| Operating Margin (Quarterly) | 2.22% |
| Return on Net Operating Assets | 3.33% |